The safety profile was much the same in each group , although drug-related adverse events were more common with losmapimod @ mg ( n = @ , @ % ) and losmapimod @ mg ( n = @ , @ % ) than with placebo ( n = @ , @ % ) and losmapimod @ mg ( n = @ , @ % ) .